Maithel Shishir K, Maloney Stephen, Winston Corrine, Gönen Mithat, D'Angelica Michael I, Dematteo Ronald P, Jarnagin William R, Brennan Murray F, Allen Peter J
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
Ann Surg Oncol. 2008 Dec;15(12):3512-20. doi: 10.1245/s10434-008-0134-5. Epub 2008 Sep 10.
Staging laparoscopy for patients with radiographically resectable pancreatic adenocarcinoma has been reported to yield an 8-15% finding of unresectable disease. Factors associated with the likelihood of subradiographic unresectable disease have not been clearly defined.
A prospectively maintained pancreatic database was reviewed and patients were identified who underwent staging laparoscopy for radiographically resectable pancreatic adenocarcinoma between January 2000 and December 2006. Preoperative carbohydrate antigen 19-9 (CA 19-9) values were assessed for their association with the presence of subradiographic unresectable disease.
Four hundred ninety-one patients underwent staging laparoscopy. Resection was performed in 80% (n = 395). Of the 96 patients with unresectable disease, 75 (78%) had metastases either in the liver (n = 60) or peritoneum (n = 15). Preoperative CA 19-9 values were available for 262 of the 491 patients. Fifty-one of these patients had unresectable disease, of which 78% were due to distant disease. The median preoperative CA 19-9 value for patients who underwent resection was 131 U/ml versus 379 U/ml for those patients with unresectable disease (P = 0.003). A receiver operating characteristics (ROC) curve was developed for preoperative CA 19-9 value and tumor resectability. The statistically optimal cutoff value was determined to be 130 U/ml. Unresectable disease was identified in 38 of the 144 patients (26.4%) with a preoperative CA 19-9 >or= 130 U/ml, and in 13 of the 118 patients (11%) with a CA 19-9 < 130 U/ml (P = 0.003). CA 19-9 values greater than 130 U/ml remained a predictor of tumor unresectability on multivariate regression analysis [hazard ratio (HR) 2.70, 95% confidence interval (CI) 1.34-5.44; P = 0.005].
In this study, preoperative CA 19-9 values were strongly associated with the identification of subradiographic unresectable disease. Preoperative CA 19-9 values may allow surgeons to better select patients for staging laparoscopy.
据报道,对影像学检查显示可切除的胰腺腺癌患者进行分期腹腔镜检查时,发现不可切除疾病的比例为8% - 15%。与亚影像学不可切除疾病可能性相关的因素尚未明确界定。
回顾前瞻性维护的胰腺数据库,确定2000年1月至2006年12月期间因影像学检查显示可切除的胰腺腺癌而接受分期腹腔镜检查的患者。评估术前糖类抗原19 - 9(CA 19 - 9)值与亚影像学不可切除疾病存在情况的相关性。
491例患者接受了分期腹腔镜检查。80%(n = 395)的患者进行了切除手术。在96例不可切除疾病的患者中,75例(78%)有肝转移(n = 60)或腹膜转移(n = 15)。491例患者中有262例有术前CA 19 - 9值。其中51例患者有不可切除疾病,其中78%是由于远处疾病。接受切除手术患者的术前CA 19 - 9值中位数为131 U/ml,而不可切除疾病患者为379 U/ml(P = 0.003)。绘制了术前CA 19 - 9值与肿瘤可切除性的受试者工作特征(ROC)曲线。确定统计学上的最佳临界值为130 U/ml。术前CA 19 - 9≥130 U/ml的144例患者中有38例(26.4%)被确定为不可切除疾病,而CA 19 - 9 < 130 U/ml的118例患者中有13例(11%)(P = 0.003)。在多因素回归分析中,CA 19 - 9值大于130 U/ml仍然是肿瘤不可切除性的预测指标[风险比(HR)2.70,95%置信区间(CI)1.34 - 5.44;P = 0.005]。
在本研究中,术前CA 19 - 9值与亚影像学不可切除疾病的识别密切相关。术前CA 19 - 9值可能有助于外科医生更好地选择进行分期腹腔镜检查的患者。